C
7.48
-0.09 (-1.19%)
| Previous Close | 7.57 |
| Open | 7.58 |
| Volume | 866,663 |
| Avg. Volume (3M) | 1,427,637 |
| Market Cap | 591,296,960 |
| Price / Earnings (TTM) | 3.67 |
| Price / Earnings (Forward) | 11.78 |
| Price / Sales | 1.91 |
| Price / Book | 1.45 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2026 |
| Profit Margin | 20.81% |
| Operating Margin (TTM) | 51.49% |
| Diluted EPS (TTM) | 0.250 |
| Total Debt/Equity (MRQ) | 0.41% |
| Current Ratio (MRQ) | 4.21 |
| Operating Cash Flow (TTM) | -13.57 M |
| Levered Free Cash Flow (TTM) | -21.07 M |
| Return on Assets (TTM) | 8.31% |
| Return on Equity (TTM) | 19.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | CorMedix Inc. | Bearish | Mixed |
AIStockmoo Score
1.4
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 1.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.38 |
|
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.08% |
| % Held by Institutions | 34.20% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 14.00 (Needham, 87.17%) | Buy |
| 14.00 (D. Boral Capital, 87.17%) | Buy | |
| Median | 14.00 (87.17%) | |
| Average | 14.00 (87.17%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 6.87 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 05 Mar 2026 | 14.00 (87.17%) | Buy | 6.30 |
| D. Boral Capital | 11 Feb 2026 | 14.00 (87.17%) | Buy | 7.43 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |